INM-405

INM-405 is a cannabinoid-based pharmaceutical candidate being developed by InMed Pharmaceuticals for the treatment of orofacial pain, including conditions such as trigeminal neuralgia. As part of InMed's pipeline of rare cannabinoid-based therapies, INM-405 is designed to leverage the analgesic and anti-inflammatory properties of specific cannabinoids to modulate pain signaling in the orofacial region. The drug is intended to provide a targeted therapeutic option for chronic pain conditions that are often poorly managed by traditional analgesics, potentially offering a better safety profile and reduced side effects compared to opioids or systemic anticonvulsants.